Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment

Ann Hematol. 2013 Nov;92(11):1577-9. doi: 10.1007/s00277-013-1748-7. Epub 2013 Apr 13.

Authors

Georg Feldmann¹, Peter Brossart, Marie von Lilienfeld-Toal

Affiliation

¹ Department of Internal Medicine 3, Center of Integrated Oncology (CIO) Cologne-Bonn, University Hospital of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany, [email protected].

PMID: 23584506
DOI: 10.1007/s00277-013-1748-7

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged, 80 and over
Antimetabolites, Antineoplastic / adverse effects*
Azacitidine / adverse effects*
Humans
Leukocytosis / chemically induced*
Leukocytosis / diagnosis
Male
Myelodysplastic Syndromes / diagnosis
Myelodysplastic Syndromes / drug therapy*
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Azacitidine